Daiichi Sankyo Company, Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
DSNKY Over the counter 2830 www.daiichisankyo.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Daiichi Sankyo Company, Limited

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Jan 21st, 2025 5:54 pm
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer - Jan 17th, 2025 10:35 pm
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m - Jan 14th, 2025 7:39 pm
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH - Jan 13th, 2025 4:00 pm
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Jan 13th, 2025 7:00 am
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC - Dec 26th, 2024 3:19 pm
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment - Dec 26th, 2024 11:40 am
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn - Dec 24th, 2024 7:00 am
Daiichi Sankyo doses first subject in Phase III AML therapy trial - Dec 11th, 2024 12:26 pm
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC - Dec 10th, 2024 2:44 pm
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML - Dec 10th, 2024 1:00 pm
Daiichi Sankyo secures breakthrough designation for NSCLC treatment - Dec 9th, 2024 5:46 pm
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Dec 9th, 2024 7:00 am
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis - Dec 6th, 2024 2:15 am
Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH - Dec 2nd, 2024 1:00 pm
Daiichi Sankyo exec on purposeful data collection - Nov 21st, 2024 5:41 pm
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time - Nov 20th, 2024 12:23 pm
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study - Nov 18th, 2024 9:01 pm
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS - Nov 13th, 2024 1:00 pm
AstraZeneca, Daiichi revise approval plans for Enhertu successor - Nov 12th, 2024 11:19 am